Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhibitors in COVID-19 and ARDS Patients.

Coagulopathies develop in patients supported with the use of extracorporeal membrane oxygenation (ECMO) and can be hemorrhagic and/or thrombophilic in spite of the use of systemic anticoagulation. The purpose this study was to examine the use of heparin and direct thrombin inhibitors (DTI) in COVID-19 patients with acute respiratory distress syndrome (ARDS) on ECMO, with a subset analysis by disease state. Following IRB approval, 570 consecutive records were reviewed of adult patients on venovenous ECMO between May 2020 and December 2021. Patients were grouped by anticoagulant use: Heparin Only (n = 373), DTI Only (bivalirudin or argatroban, n = 90), or DTI after Heparin (n = 107). The effect of anticoagulant grouping was assessed using Bayesian mixed-effects logistic regression adjusting for age, body mass index (BMI), gender, days of mechanical ventilation prior to ECMO, indication for ECMO support, hepatic and renal failure, hours on ECMO, hours off anticoagulation, coagulation monitoring target, and hospital. The primary endpoint was circuit failure requiring change-out with secondary endpoints of organ failure and mortality. Regression-adjusted probability of circuit change-outs were as follows: DTI after Heparin patients-32.7%, 95% Credible Interval [16.1-51.9%]; DTI Only patients-23.3% [7.5-40.8%]; and Heparin Only patients-19.8% [8.1-31.3%]. The posterior probability of difference between groups was strongest for DTI after Heparin vs. Heparin Only (97.0%), moderate for DTI after Heparin vs. DTI Only (88.2%), and weak for DTI Only vs. Heparin only (66.6%). The occurrence of both hepatic and renal failure for DTI Only and DTI after Heparin patients was higher than that of Heparin Only patients. Unadjusted mortality was highest for DTI after Heparin (64.5%) followed by DTI Only (56.7%), and Heparin Only (50.1%, p = 0.027). DTI after Heparin was associated with an increased likelihood of circuit change-out. Unadjusted hepatic failure, renal failure, and mortality were more frequent among DTI patients than Heparin Only patients.

[1]  Paramita Paul,et al.  Current challenges in different approaches to control COVID-19: a comprehensive review , 2022, Bulletin of the National Research Centre.

[2]  Diego Velasco-Rodríguez,et al.  A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report , 2022, Hematology.

[3]  A. Scandroglio,et al.  Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors , 2022, Journal of Cardiothoracic and Vascular Anesthesia.

[4]  J. Veličković,et al.  D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia , 2022, Oxidative medicine and cellular longevity.

[5]  A. Sestokas,et al.  Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival , 2022, Annals of Thoracic Surgery.

[6]  P. Wells,et al.  Thromboprophylaxis in Patients With COVID-19 , 2022, Chest.

[7]  K. Lewandowska,et al.  Thromboprophylaxis in patients with Covid-19 , 2022, Acta Angiologica.

[8]  E. Fan,et al.  2021 ELSO Adult and Pediatric Anticoagulation Guidelines. , 2022, ASAIO journal.

[9]  T. Welte,et al.  Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation: Differences Between COVID-19 and Other Viral Acute Respiratory Distress Syndrome , 2022, Critical care medicine.

[10]  D. Brodie,et al.  Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis , 2021, Intensive Care Medicine.

[11]  R. Kapoor,et al.  Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support , 2021, Journal of Cardiothoracic and Vascular Anesthesia.

[12]  L. Sattler,et al.  Argatroban for Anticoagulation in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019 , 2021, Critical care explorations.

[13]  H. ten Cate Surviving Covid-19 with Heparin? , 2021, The New England journal of medicine.

[14]  Christopher M. Horvat,et al.  Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 , 2021, The New England journal of medicine.

[15]  L. Camporota,et al.  A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation , 2021, Critical care medicine.

[16]  B. Zieger,et al.  Hypercoagulopathy, acquired coagulation disorders and anticoagulation before, during and after extracorporeal membrane oxygenation in COVID-19: a case series , 2021, Perfusion.

[17]  R. Rivosecchi,et al.  Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin* , 2021, Critical care medicine.

[18]  D. Brodie,et al.  Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization , 2021, ASAIO journal.

[19]  T. Rice,et al.  Bleeding, Thromboembolism, and Clinical Outcomes in Venovenous Extracorporeal Membrane Oxygenation , 2020, Critical care explorations.

[20]  Hongtao Zhang,et al.  Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19 , 2020, Antibodies.

[21]  Lin Sun,et al.  Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation , 2020, Journal of Cardiothoracic and Vascular Anesthesia.

[22]  Kholoud F. Aliter,et al.  Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19 , 2020, Cardiovascular Drugs and Therapy.

[23]  A. Fauci,et al.  Emerging Pandemic Diseases: How We Got to COVID-19 , 2020, Cell.

[24]  Salim E. Olia,et al.  A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19 , 2020, Journal of Cardiothoracic and Vascular Anesthesia.

[25]  T. Seelhammer,et al.  Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19 , 2020, Journal of Cardiothoracic and Vascular Anesthesia.

[26]  J. Connors,et al.  Thromboinflammation and the hypercoagulability of COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[27]  N. Smischney,et al.  Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation , 2019, World journal of critical care medicine.

[28]  G. Schears,et al.  Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques , 2017, Vox sanguinis.

[29]  E. Conway,et al.  Cross Talk Pathways Between Coagulation and Inflammation. , 2016, Circulation research.

[30]  Isaac Subirana,et al.  Building Bivariate Tables: The compareGroups Package for R , 2014 .

[31]  M. Ranucci Bivalirudin and post-cardiotomy ECMO: a word of caution , 2012, Critical Care.

[32]  M. Ranucci,et al.  Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation , 2011, Critical care.

[33]  J. Ansell,et al.  Direct thrombin inhibitors. , 2011, British journal of clinical pharmacology.

[34]  P. Aylward,et al.  Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender , 2002, Clinical pharmacology and therapeutics.

[35]  Gail,et al.  ELSO Adult and Pediatric Anticoagulation Guidelines , 2022 .

[36]  R. Rivosecchi,et al.  841: Comparison of 4-Factor Prothrombin Complex Concentrate Dosing Strategies for Warfarin Reversal , 2020 .

[37]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .